Intercure Ltd

InterCure Ltd. engages in the business of medical cannabis and biomedicine. It operates through the Investments in Biomed Portfolio Companies and Investments in Medical Cannabis Companies segments. The company was founded by Benjamin Gavish and Erez Gavish on November 20, 1994 and is headquartered in Herzliya, Israel.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

InterCure reports record 2022 revenues, poised for global expansion

InterCure had a successful year in 2022, achieving record revenues and positioning itself for global expansion. The company's focus on the Israeli market, expansion of cultivation facilities, and addition of new product strains have been key drivers of growth. Despite challenges in patient procurement and regulatory complexities, InterCure is well-prepared to leverage opportunities in international markets.

InterCure reports record revenue and positive cash flow for 2022

InterCure's Q4 2022 earnings call highlighted a successful 2022, with record revenue and positive cash flow. The company's focus on leading the Israeli market, scaling up operations, and navigating market dynamics and regulatory differences positions it for continued growth. Despite industry challenges, InterCure is well-prepared to capitalize on opportunities presented by pricing trends and prescription reforms.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

InterCure Ltd. engages in the provision of business of medical cannabis and biomedicine. It operates through the Investments in Biomed Portfolio Companies in the Biomed Sector and Investments in the Medical Cannabis Sector segments. The company was founded by Benjamin Gavish and Erez Gavish on November 20, 1994 and is headquartered in Herzliya, Israel.

InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR), which is doing business as Canndoc, has signed a definitive agreement to acquire Cann Pharmaceutical Ltd.

InterCure To Acquire Israel-Based Medical Cannabis Producer Better For $35M

Marking the First Major Consolidation in Pharmaceutical Grade Medical Cannabis Market

InterCure Signs Definitive Agreement to Acquire Multi-National Medical Cannabis Producer “Better”

Canopy Growth

InterCure Ltd. INCR INCR INCR, doing business as Canndoc, announced record preliminary financial results for the fourth quarter of 2021.

InterCure Reports Record Preliminary 2021 Fourth Quarter Revenue - 3 Times YoY and 24% QoQ Growth.

Estimated revenue reaches over CAD$31 million (a record NIS 77 million)

InterCure Reports Record Preliminary 2021 Fourth Quarter Revenue - 3 Times YoY and 24% QoQ Growth

Cannabis brand Cookies announced Thursday its international expansion into Europe through a partnership with Israel-based marijuana company InterCure (NASDAQ:INCR). The parties signed a multi-year deal under which InterCure will establish Cookies stores and medical cannabis pharmacies in Austria and the United Kingdom in early 2022.

Berner's Cookies Enters Europe Via Partnership With InterCure, Will Open Stores In Austria & U.K.

Leading Global Cannabis Company InterCure Partners with Cookies to Open Retail Locations in Austria and the U.K. in Early 2022 Leading Global Cannabis Company InterCure Partners with Cookies to Open Retail Locations in Austria and the U.K. in Early 2022

InterCure Announces European Expansion with International Cannabis Brand Cookies

SAN FRANCISCO--(BUSINESS WIRE)--Iconic cannabis brand Cookies today announced its international expansion into Europe through a partnership with Israel-based InterCure (NASDAQ: INCR), the leading, profitable and fastest-growing cannabis company outside North America. The parties entered into a multiyear deal under which InterCure will establish Cookies stores and medical cannabis pharmacies in Austria and the United Kingdom in early 2022. "As we focus on new territories, it's vital our customer

International Cannabis Brand Cookies and InterCure Announce European Expansion

Mr. Rabinovitch to participate in the ‘International' panel at 11:50 a.m. ET on Tuesday, November 30, 2021 Mr. Rabinovitch to participate in the ‘International' panel at 11:50 a.m. ET on Tuesday, November 30, 2021

InterCure to Participate in Cowen's 4th Annual Cannabis Conference

Aurora Cannabis

Entegris

Greenlane Holdings

Neptune Wellness Solutions Inc.

OrganiGram Holdings Inc.

Advisorshares Poseidon Dynamic Cannabis ETF

Spotify

Teradyne

cbdMD Inc

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.

It's Been a Blazing Hot Week for These 12 Cannabis Stocks

InterCure Ltd. (INCR) CEO Alex Rabinovitch on Q3 2021 Results - Earnings Call Transcript

Israeli cannabis company InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR), which does business as Canndoc, released its third-quarter financial results Monday revealing all-time record quarterly revenue of CA$25 million ($19.97 million), three times greater than Q3 2020.

Israeli Cannabis Co. Intercure Posts Record Q3 Revenue Of CA$25M, Dispenses One Ton Of GMP Medical Cannabis In Oct.

Seventh consecutive quarter of high double-digit, sequential revenue growth

InterCure Announces Record Third Quarter Financial Results with 3 Times YoY Revenue Growth and 36% QoQ Growth

With addition of four new pharmacies , InterCure 's dedicated chain GIVOL now has 20 locations across Israel

InterCure Expands Pharmacy Chain in Israel; Surpasses One-Ton Medical Cannabis Products Dispensed Per Month

InterCure Ltd. (NASDAQ: INCR) (TSX:INCR) (TASE: INCR), doing business as Canndoc,  r eported Monday  preliminary unaudited revenue of CA$24 million ($19.41 million)  for the third quarter of 2021.

Israeli Cannabis Co. InterCure's Shares Up On Preliminary Q3 Record Revenue Of $19.41M

Achieved a number of firsts and records including:

InterCure Announces Record Preliminary Third Quarter Revenue of CAD$24 million - 3 Times YOY and 36% QOQ Growth

NEW YORK, TORONTO and HERZLIYA, Israel, Oct. 12, 2021 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the “Company”) today announced that CEO Alexander Rabinovitch purchased, throughout the month of September 2021, a total of 423,501 shares of the Company's common stock.

InterCure CEO Alex Rabinovitch Purchases Over 420,000 Shares of Company Stock in The Open Market

InterCure is the most profitable cannabis company outside North America and recently uplisted to Nasdaq. Israel's former Prime Minister, Chairman Ehud Barak and CEO Alex Rabinovitch join the podcast to discuss Israel's cannabis landscape and what investors can expect going forward.

InterCure: Internationally Profitable Cannabis (Podcast Transcript)

InterCure is the most profitable cannabis company outside North America and recently uplisted to Nasdaq.

InterCure: Internationally Profitable Cannabis (Podcast)

InterCure reported exceptional Q2'21 revenues with numbers up 400% over last year. The Israeli cannabis company recently uplisted to the Nasdaq to limited fanfare.

InterCure: Ignored Uplisting

NEW YORK and TORONTO and HERZLIYA, Israel, Sept. 8, 2021 /PRNewswire/ -- InterCure Ltd.

InterCure to Webcast Live at VirtualInvestorConferences.com September 9th

Achieved record revenue of NIS 45 million (over CAD$17 million), an increase of 400% year-over-year and 37% quarter-over-quarter

InterCure Re-Announces its Record-Breaking Second Quarter Financial Results With 4 Times YOY Revenue Growth - Following NASDAQ Listing

InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) revealed on Thursday that it will buy strategic assets from Cannomed (TASE: CNMD), an Israel-based company and owner of a pharmacy chain specializing in dispensing medical cannabis.

InterCure To Buy Strategic Assets From Cannomed On Heels Of Its NASDAQ Debut

One of Israel's largest cannabis companies, InterCure Ltd. (NASDAQ:INCR) began trading on the NASDAQ Global Market on Wednesday.

Israeli Cannabis Co. InterCure Begins Trading On NASDAQ, Chaired By Former Prime Minister

Acquisition includes two medical cannabis dispensing pharmaci es , another pharmacy in the process of receiving its license and a medical cannabis patient support center

InterCure Continuing its Medical Cannabis Consolidation Strategy, Announces Strategic Acquisition of Cannomed Pharmacy Chain

The leading cannabis company outside North America debuts today on Nasdaq The leading cannabis company outside North America debuts today on Nasdaq

News for Intercure Ltd Stock (INCR)